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Abstract
Introduction: Percutaneous transfemoral access approach for the transcatheter aortic valve implantation (TAVI) is still
associated with signiﬁcant vascular complications. Hence, evaluation of best techniques for the reduction of vascular
injury via the femoral access remains a key subject of research.
Aim: We report on a single centre's experience with TAVI performed via the Femoral Artery Minimal Surgical Access
(MSA) and percutaneous approach (PC). The primary endpoints were to evaluate the incidents of vascular complications
by comparing the MSA versus the PC approach according to the VARC-2 criteria. The secondary endpoint included the
impact of vascular complications on the in-hospital 30-day mortality and morbidity.
Material and methods: Between June 2010 and September 2020, two hundred and thirty-seven consecutive patients who
underwent TAVI for severe symptomatic aortic stenosis in our department were divided into two groups: patients treated
using the femoral artery minimal surgical access (n ¼ 173), and patients treated using the percutaneous approach (n ¼ 64).
Results: Overall rate of access site complications according the VARC-2 were signiﬁcantly more frequent in the
percutaneous cohort (n ¼ 12/64, 18.8% vs n ¼ 2/173, 1.1%, p ¼ 0.0012). The minor access complications including haematoma, bleeding, aneurysm, dissection, stenosis, seroma and infection were more frequent in the PC group (n ¼ 8/64,
12.5% vs n ¼ 2/173, 1.1%, p < 0.001). There were no major access site complications and hospital deaths in the MSA
group, which was statistically signiﬁcant (p < 0.001). Major access complications (n ¼ 4, 6.3%, p < 0.001) and hospital
death (n ¼ 2, 3.1%, p < 0.001) were found in the PC cohort.
Conclusions: The minimal surgical access approach provided direct and controlled access and signiﬁcantly reduced the
incidence of access site vascular complications in our TAVI patients. It also signiﬁcantly reduced the in-hospital vascularrelated mortality and morbidity. Though both approaches are complementary to each other, minimal surgical access
approach would be a better choice for a calciﬁed or tortuous femoral artery, and for a relatively small femoral artery diameter.
Keywords: Aortic stenosis, Vascular complications, TAVI, Aortic valve replacement

1. Background

T

ranscatheter aortic valve implantation (TAVI)
has emerged as an essential therapeutic option
in the management of severe, symptomatic aortic
valve stenosis initially in patients at high risk for

open surgical replacement. Since the PARTNER trial
demonstrated that TAVI is not inferior to surgical
aortic valve replacement (AVR) and showed similar
mortality at 30 days and up to two years in surgical
high-risk patients, the indication of TAVI progressed
to include patients with lower surgical risk [1].
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In the early days, there was no standardized
criteria to deﬁne vascular complications (VC) until
the Valve Academic Research Consortium (VARC-1
and VARC-2) established [2,3] and provided a
standardized reference to researchers. Vascular
complication rates were comparatively high in the
early days of TAVI.
Despite the evolution of TAVI valves by (1)
reducing their proﬁle, (2) the improvement of the
delivery system to reduce the sheath diameter sizing
down from 22 to 24 to 14 French, (3) the increasing
experience of the physicians’ implanting techniques, (4) the use of an assisting imaging tool to
visualize the access site and (5) the improvement of
vascular closure device, vascular complications
remain a major concern for the operators. VC in
TAVI are associated with increased in-hospital
morbidity and mortality [4,5,10,12]. Mach et al. reported a higher hospital mortality in the percutaneous group (5.2% vs 1.9%, p ¼ 0.075) and
Olasi
nska-Wisniewska et al. demonstrated similar
results with a signiﬁcantly higher in-hospital mortality (8.8% vs 1.5%, p ¼ 0.1) for the PC group.
The transfemoral route remains the preferred access for the TAVI valve delivered either through
percutaneous or surgical access. The risks and
beneﬁts of each access strategy were studied
extensively. Recent studies reported surgical access
provided controlled access and resulted in signiﬁcantly lower minor VC even though there was no
major VC difference [7,8,10,13]. However, Olasi
nska-Wisniewska et al. reported that both minor
and major access site complications were signiﬁcantly decreased in the surgical cohort (35.5% vs
7.5%, p ¼ 0.0012) and both minor and major access
site complications were signiﬁcantly less frequent
in cut-down group (p ¼ 0.04 and 0.016 respectively).
A few studies reported that percutaneous approach
complementary with surgical access [7,10,13] was
less invasive with a shorter hospital length of
stay [11].
The aim of this observational retrospective study
is to report our single center experience and outcomes with TAVI performed through femoral access
site by either percutaneous approach or minimal
surgical access.

2. Method
2.1. Patient population
All patients undergoing elective transfemoral
TAVI for severe aortic valve stenosis between June
2010 until September 2020 at the Department of
Cardiac Science, King Abdulaziz Cardiac Centre,

Abbreviations
AVR
MDCT
MSA
PC
TAVI
VC
VARC

aortic valve replacement
multidetector computed tomography
minimal surgical access
percutaneous approach
transcatheter aortic valve implantation
Vascular complication
Valve Academic Research Consortium

Riyadh, Saudi Arabia were retrospectively analyzed.
Two hundred and thirty-seven (n ¼ 237) patients
were enrolled in this study; early-learning experience before June 2010 was excluded. The study
population was divided into two groups according
to the vascular access protocol: (Fig. 1) minimal
surgical access (MSA) (n ¼ 173) and percutaneous
transfemoral access (PC) (n ¼ 64). A multidisciplinary heart team consisting of a structural interventional cardiologist, a TAVI certiﬁed cardiac
surgeon and an echocardiographer assessed all
cases considering the calculated perioperative risk
using the logistic EuroSCORE II as well as the patients’ characteristics for a consensus therapeutic
strategy. The local Ethics Committee approved the
study (RC19/425/R20191127) and written informed
consent was obtained from all patients before the
procedure.
2.2. Pre-operative screening imaging and vascular
access protocol
The selection of vascular access was done by the
heart team through detailed reviewing of all the
routine pre-operative imaging. According to our
vascular access protocol (Fig. 1), a minimum of
5.5 mm vessel diameter was considered suitable for
TAVI enrollment.
The pre-operative screening consisted of the use
of multidetector computed tomography (MDCT)
and angiography examination which was performed
using the dual Source CT (Somatom Deﬁnition,
Siemens) to assess the accuracy of vascular anatomy. MDCT provides clear and complete threedimensional assessment of the iliofemoral system,
multiple plane reconstructions of aortic annulus
measurements, extent of vessel calciﬁcation and
tortuosity, and the morphology of the entire aorta.
The vessel diameter was deﬁned as the distance
between the internal vessel walls. In the case of a
heavily calciﬁed vessel, the actual diameter was the
vessel lumen.
In the percutaneous transfemoral access (PC)
cohort, the common femoral artery (CFA) was the
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Fig. 1. Flow diagram for patient selection to undergo percutaneous transfemoral access (PC) or femoral artery minimal surgical access (MSA) TAVR
procedure.

access site of choice for all the PC TAVI procedures.
Circumferential calciﬁed and high femoral bifurcations were excluded in this cohort. PC was
performed in the standard fashion using the Seldinger technique. Hemostasis after sheath removal
was achieved using the double Perclose Proglide 6F
Suture-Mediated Closure System (Abbott Vascular,
Santa Clara, CA, USA).
The femoral artery minimal surgical access (MSA)
cohort was led by a cardiac surgeon. A 15e20 mm
minimal incision was made starting distally at the
inguinal ligament and directly over the femoral artery (Fig. 2). Subcutaneous tissue was carefully and
minimally dissected, and the femoral artery was
prepared by placing e a purse-string suture at a
non-calciﬁed site using 5/0 polypropylene suture as
indicated in Fig. 3 site A. Vascular access was gained
through a separate skin puncture as indicated in
Fig. 3 site B and puncture of the femoral artery
under direct visualization. The femoral artery
puncture site was gradually dilated using vascular
dilators 7, 9 and 12 French sequentially. A 14, 16 or
18 French Medtronic sheath then inserted. The sutures were tied after the removal of the Valve delivery system and haemostasis was secured (Fig. 4).
2.3. Prosthesis size selection
The ﬁnal decision on implanted prosthesis size
was left at the discretion of the physicians performing the procedure based on MDCT aortic
annulus measurements.
Medtronic self-expanding CoreValve™ with sizes
26 & 29 mm, Evolut™ R with sizes 23, 26, 29 mm and

Evolut™ PRO with sizes 23, 26, 29 mm (Medtronic,
Minneapolis, MN, USA) transcatheter aortic valve
implantation (TAVI) devices were implanted in our
patient cohort.
An 18 French delivery system (n ¼ 15, 5.5%) was
used for CoreValve™ with sizes 26 & 29 mm. Only a
14 French delivery system (n ¼ 214, 78.4%) was used
for Evolut™ R with valve sizes 23, 26, 29 mm, and a 16
French delivery system (n ¼ 8, 2.9%) was used for
Evolut™ PRO with valve sizes 23, 26, 29 mm (Table 1).
2.4. Study endpoints
The clinical endpoints of this study were categorized using Valve Academic Research Consortium
(VARC-2) criteria [3]. The primary endpoints were
to evaluate the incidents of vascular complications
by comparing MSA versus the PC approach according to the VARC-2 criteria. The secondary
endpoint included the impact of vascular complications on the in-hospital 30 days mortality and
morbidity.
2.5. Statistical analysis
Statistical analysis was undertaken using SPSS.
Continuous variables, presented as means and
standard deviation (±SD) or median and interquartile range, and continuous variables were analysed using the unpaired t-test. Categorical
variables as absolute numbers and percentages and
categorical variables were analysed with Fisher's
exact test. A p value of <0.05 was considered statistically signiﬁcant for all analyses.
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Fig. 3. A. The minimal access incision (A) with a separate access (B) for
the delivery system.

Fig. 2. The view of the minimal incision dimension.

3. Results
The baseline characteristics of the study population are displayed in Table 2. The study population
enrolled less patients in the percutaneous transfemoral access group compared to the minimal
surgical access group (n ¼ 173, 73% vs n ¼ 64, 27%).
The study cohort comprised an almost equal distribution between males (51.6% in PC and 46.2% in
MSA) and females (48.4% in PC and 53.8% in MSA)
with a mean age of 72 and 74 years for the PC and
MSA group respectively.
The baseline characteristics of our patient groups
were comparable. There were no signiﬁcant differences between the two groups in obesity level, hypertension, prior coronary artery bypass grafting,
prior percutaneous coronary intervention, congestive heart failure, cerebrovascular event and EuroScore II. Incidence of diabetes mellitus and NYHA
class IIIwas higher in minimal surgical access group
compared to the percutaneous transfemoral access
group (61.8% vs 53.1%, p ¼ 0.039) and (40% vs
28.1%, p ¼ 0.046) respectively. Approximately 47%
(n ¼ 111/273) of patients were in New York Heart
Association functional class III/IV. More patients in
the MSA group were in NYHA class III/IV (49.2% in
MSA vs 40.7% in PC, n ¼ 85 vs 26). The comparison

of baseline clinical characteristics revealed a significantly higher risk proﬁle in the surgical group,
which was expressed by higher NYHA class III/IV
and higher number of diabetic patients.
A total of 237 valves were implanted; Evolut™ R
valves were mainly (78.4%) used followed by CoreValve® (5.5%) and Evolut™ PRO (2.9%). 14 French

Fig. 4. The ﬁnal skin closure.
Table 1. Prosthesis and sheath size used in TAVI group.
Valve Brand

Patient
number (%)

Sheath size
(French)

Vascular access
MSA

PC

CoreValve®
Evolut™ R
Evolut™ PRO
Total number

15 (5.5%)
214 (78.4%)
8 (2.9%)
237 (100%)

18
14
16

15 (100%)
152 (71%)
6 (75%)
173 (73%)

0 (0%)
62 (29%)
2 (25%)
64 (27%)
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Table 2. Baseline patient characteristics for the PC and MSA group.
Characteristics

PC Group (n ¼ 64)

MSA Group (n ¼ 173)

P value

Mean age (Years)
Gender
Male no. (%)
Female no. (%)
BMI (Kg/m2)
Diabetes Mellitus Type II no.(%)
Hypertension no.(%)
Prior CABG/PCI no.(%)
CHF no.(%)
NYHA Class no. (%)

72 (68e77)

74 (70e79)

0.965

33 (51.6%)
31 (48.4%)
28.9 (24.8e33.6)
34 (53.1%)
45 (70.3%)
15 (23.4%)
7 (10.9%)
11 (17.1%)
27 (42.2%)
18 (28.1%)
8 (12.6%)
2 (3.1%)
6.86 ± 2.15

80 (46.2%)
93 (53.8%)
35.2 (30.2e39.7)
107 (61.8%)
109 (63.0%)
37 (21.4%)
40 (23.1%)
24 (13.8%)
64 (37.0%)
69 (40.0%)
16 (9.2%)
9 (5.2%)
5.47 ± 1.48

0.644
0.633
0.586
0.039
0.345
0.696
0.430
0.530
0.659
0.046
0.582
0.960
0.988

Cerebro vascular event no.(%)
Euroscore II (mean ± SD)

I
II
III
IV

BM:I body mass index 35 is considered as obese, CABG: coronaryeartery bypass grafting, PCI: percutaneous coronary intervention,
CHF: Congestive Heart Failure, NYHA: New York Heart Association.
Table 3. Major and minor vascular complications (Valve Academic Research Consortium-2 deﬁnitions) in the PC and MSA group.
Event number (%)

PC Group (n ¼ 64)

MSA Group (n ¼ 173)

P value

Access site complications
Minor access complication (Haematoma, bleeding, aneurysm,
dissection, stenosis, seroma, infection)
Major access complications retroperitoneal haematoma,
ileo-femoral rupture
Hospital death

12 (18.8%)
8 (12.5%)

2 (1.1%)
2 (1.1%)

0.0012
<0.001

4 (6.3%)

0

<0.001

2 (3.1%)

0

<0.001

sheath size (n ¼ 214, 90.3%) were mainly used in
both the MSA and PC cohort (n ¼ 152, 87.9% vs
n ¼ 62, 96.9%). MSA (73% vs 27%) was a predominant strategy in our study.
Overall rate of access site complications according
the VARC-2 were signiﬁcantly more frequent in the
percutaneous cohort (n ¼ 12/64, 18.8% vs n ¼ 2/173,
1.1%, p ¼ 0.0012) (Table 3). The minor access complications including haematoma, bleeding, aneurysm, dissection, stenosis, seroma and infection
were more frequent in the PC group (n ¼ 8/64,
12.5% vs n ¼ 2/173, 1.1%, p < 0.001). There were no
major access site complications or hospital deaths in
the MSA group, which was statistically signiﬁcant
(p < 0.001). However, major access complications
(n ¼ 4, 6.3%, p < 0.001) and hospital death (n ¼ 2,
3.1%, p < 0.001) were found in the PC cohort.

et al. (2013) found a rate of 53.01% early vascular
complications in their cohort in which 20.48% were
major and 32.53% were minor incidents [6]. A Polish
group reported 20.8% VC in 745 patients (Kochman
2018) while minor VC was signiﬁcantly higher in the
PC cohort (16.8% vs. 9.7%, p < 0.01) [7].
After VARC-2 standardized the deﬁnition of
reporting the VC outcomes and the newer generation TAVI valves and delivery system were available, VC signiﬁcantly declined in the recent years.
The Abdelaziz et al. group did a meta-analysis review with 5859 patients and reported a major
vascular complication of 8.7% and 8.5% in the
percutaneous vs cut down group respectively [8].
Pellegrini et al. reported a major vascular complication rate of 8% [9]. Mach et al. showed VARC-2
access complications occurred signiﬁcantly more
often in percutaneous group than the cut down
group (20.4% vs 8.5%), and minor complications
were signiﬁcantly higher in the PC compared to cutdown (14.4% vs 2.5%) [10]. Gennari et al. reported
4.5e5.1% minor vascular complications and around
2.7% major complications in their study [11].
The minimal surgical access approach in our
study signiﬁcantly reduced the incidence of access
site vascular complications in our TAVI patients,
and signiﬁcantly reduced the in-hospital vascularrelated mortality and morbidity.

4. Discussion
The PARTNER trial [1] found that patients treated
with TAVR had 15.3% major VC and 11.9% minor
vascular complications within 30 days of the procedure. Olasi
nska-Wisniewska et al. (2017) reported
access site complication rates signiﬁcantly decreased
from 35.3% to 7.5% between the percutaneous and
the cut down group [4]. Genereux et al. reported a
vascular complication rate of 11.9% in a meta-analysis with 3519 patients [5]. Czerwin'ska-Jelonkiewicz
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Our results are consistent with the previous
studies that compared the two different vascular
access techniques. Spitzer et al. reported that the
overall rate of VARC-2 access site complications
(20.6% vs 8.1%, P ¼ 0.04) and bleeding complications (18.1% vs. 4.4%; P ¼ 0.029) were signiﬁcantly
less frequent in the cut-down cohort. Minor complications were signiﬁcantly more frequent in the
PC group (p ¼ 0.04).
Mach et al. showed that the overall VARC-2 access complications (p ¼ 0.037) and bleeding complications (p ¼ 0.01) were signiﬁcantly lower in the
cut-down group. Minor complications were signiﬁcantly higher in the percutaneous group (p ¼ 0.04).
In contrast to the Spitzer et al. and Mach et al.
reports which showed that major complications and
hospital deaths were not signiﬁcantly different between two groups (p ¼ 0.19, p ¼ 0.341), the surgical
group in our study had signiﬁcantly lower rate of
major complications in MSA (n ¼ 0 vs n ¼ 4,
p < 0.001). This ﬁnding occurred despite having a
higher proportion of patients with diabetes and
NYHA class III/VI. The minimal surgical access
technique in which the operator gains direct and
controlled access to the femoral artery through a
separate skin puncture is believed to be the main
contributor in the reduction of major complications
in our cohort. The small incision, which is less than
20 mm, provided a less invasive access than a typical
20e30 mm cut-down incision and allowed just
enough room for the delivery system and the sheath
to pass through, minimizing the risk of dissecting
the femoral artery particularly, if it is calciﬁed.
Hospital death was signiﬁcantly higher in our PC
cohort (p < 0.001). The two hospital deaths were
related directly to the major dissection of the ileofemoral artery. Direct access to the femoral artery
that was obtained in the minimal surgical access
technique group resulted in less rupture and
bleeding.
The size of delivery sheaths is one of the major
risk factors of access site complications. In our study
population, approximately 78% (n ¼ 214/237) of 14French sheaths were used in both groups. Almost all
the PC cohort (n ¼ 62/64, 97%) used 14-French
sheaths during the TAVI. Despite a relatively
smaller sheath used in the PC, the overall vascular
site complications are signiﬁcantly higher
(P ¼ 0.0012). The larger 18-French sheaths (n ¼ 15/
173, 5.5%) were only used for the MSA cohort and
did not result in any major access site complication.
The direct controlled access by MSA is believed to
have reduced the site complications.

5. Conclusion
The minimal surgical access approach provided a
direct and controlled vascular access and signiﬁcantly reduces the incidence of access site vascular
complications in our TAVI patients. It also signiﬁcantly reduced the in-hospital vascular-related
mortality and morbidity. Though both approaches
are complementary to each other, minimal surgical
access approach would be a better choice for calciﬁed, tortuous, and relatively small femoral artery
diameter vessels.
5.1. Limitation
The limitations of our study are due to its retrospective, single center, non-randomized nature. The
small number of patients enrolled over a long
period of time may affect the operator's learning
experience. Even though the heart team members
remained stable throughout the study, there was
some bias and preference on the mode of access
particularly for some more complex cases. The
collected data did not include speciﬁc computed
tomography ﬁndings such as the vessel calciﬁcation,
diameter and tortuosity, sheath to femoral artery
ratios and the post-operative morbidity data, which
did not allow assessment of their inﬂuence on the
outcome in both access strategies.
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